Literature DB >> 10810286

Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm.

J Arola1, J Liu, P Heikkilä, V Ilvesmäki, K Salmenkivi, R Voutilainen, A I Kahri.   

Abstract

Inhibins are gonadal glycoprotein hormones whose main endocrine function is to inhibit pituitary FSH secretion. In addition to testes and ovaries, other steroid-producing organs are sites of inhibin alpha subunit expression. To study the role of inhibins in human adrenal gland, we screened a panel of 150 adrenals (10 normal adrenals, 25 adrenocortical hyperplasias, 65 adrenocortical adenomas, 30 adrenocortical carcinomas and 20 phaeochromocytomas) for inhibin alpha expression. mRNA levels of inhibin alpha subunit were studied in 57 samples and all tissues were stained immunohistochemically with an inhibin alpha subunit-specific antibody. Inhibin alpha mRNA was detected in all adrenocortical tissues. Virilizing adenomas possessed a 10-fold higher median inhibin alpha mRNA expression than did normal adrenals. Bilaterally and nodularly hyperplastic adrenals and other than virilizing adrenocortical tumours had their median inhibin alpha mRNA levels close to those of normal adrenals. Immunohistochemically, inhibin alpha subunit was detectable in all normal and hyperplastic adrenals, as well as in 73% of the adrenocortical tumours. However, the percentage of inhibin alpha-positive cells varied greatly in different tumour types. The median percentage of positive cells was 10 in non-functional and Conn's adenomas, 30 in Cushing's adenomas and 75 in virilizing adenomas. In malignant adrenocortical tumours the median percentage of inhibin alpha-immunopositive cells was 20 in non-functional carcinomas, 30 in Conn's carcinomas, 65 in Cushing's carcinomas and 75 in virilizing carcinomas. All phaeochromocytomas were negative for inhibin alpha subunit both at the mRNA level and immunohistochemically. Our data show that inhibin alpha subunit is highly expressed in both normal and neoplastic androgen-producing adrenocortical cells, with less expression in cortisol-producing and hardly any in aldosterone-producing cells. This suggests a specific role for inhibins in the regulation of adrenal androgen production. We did not find any significant difference in inhibin alpha expression between benign and malignant adrenocortical tumours. Thus inhibin alpha gene does not seem to have a tumour suppressor role in human adrenal cortex.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810286     DOI: 10.1677/joe.0.1650223

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  13 in total

Review 1.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 2.  Discerning malignancy in resected adrenocortical neoplasms.

Authors:  H Sasano; T Suzuki; T Moriya
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors.

Authors:  Mauro Papotti; Eleonora Duregon; Marco Volante; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

4.  Expression of Wnt and TGF-β pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness.

Authors:  Helka Parviainen; Anja Schrade; Sanne Kiiveri; Renata Prunskaite-Hyyryläinen; Caj Haglund; Seppo Vainio; David B Wilson; Johanna Arola; Markku Heikinheimo
Journal:  Pathol Res Pract       Date:  2013-06-21       Impact factor: 3.250

5.  Virilising adrenocortical tumours in children.

Authors:  Walter Bonfig; Iris Bittmann; Susanne Bechtold; Birgit Kammer; Vera Noelle; Sissi Arleth; Klemens Raile; Hans-Peter Schwarz
Journal:  Eur J Pediatr       Date:  2003-06-14       Impact factor: 3.183

6.  Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.

Authors:  Julie Lang; Anna Capasso; Kimberly R Jordan; Jena D French; Adwitiya Kar; Stacey M Bagby; Jacob Barbee; Betelehem W Yacob; Lia S Head; Kenneth D Tompkins; Brian M Freed; Hilary Somerset; Toshimasa J Clark; Todd M Pitts; Wells A Messersmith; S Gail Eckhardt; Margaret E Wierman; Stephen Leong; Katja Kiseljak-Vassiliades
Journal:  J Clin Endocrinol Metab       Date:  2020-01-01       Impact factor: 5.958

Review 7.  Reduced quality and accelerated follicle loss with female reproductive aging - does decline in theca dehydroepiandrosterone (DHEA) underlie the problem?

Authors:  Judith H Ford
Journal:  J Biomed Sci       Date:  2013-12-13       Impact factor: 8.410

Review 8.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.

Authors:  Kerollos N Wanis; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2015-03-24       Impact factor: 2.754

9.  Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation.

Authors:  Johannes Hofland; Jacobie Steenbergen; Jacoba M Voorsluijs; Michael M P J Verbiest; Ronald R de Krijger; Leo J Hofland; Wouter W de Herder; Andre G Uitterlinden; Richard A Feelders; Frank H de Jong
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

10.  Laparoscopic Treatment of Adrenal Tumors: A Single-Center Experience with 58 Patients.

Authors:  Aziz Ari; Kenan Buyukasik; Cihad Tatar; Ozgur Segmen; Feyzullah Ersoz; Soykan Arikan; Feray Gunver; Serkan Sari
Journal:  Surg Res Pract       Date:  2016-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.